Park­er In­sti­tute, MD An­der­son and Seres de­vel­op­ing a mi­cro­bio­me/PD-1/L1 com­bo; CRISPR-Cas an­timi­cro­bial biotech Lo­cus rais­es $17M

→ Just days ago, MD An­der­son re­searcher Jen­nifer War­go and col­leagues pub­lished new re­search that showed how the gut mi­cro­bio­me played a big role in de­ter­min­ing whether or not a check­point ther­a­py could help save your life. This morn­ing, MD An­der­son and the sci­en­tif­ic net­work afi­ciona­dos at the Park­er In­sti­tute have put a deal to­geth­er to col­lab­o­rate with lead­ing mi­crio­bio­me biotech Seres on a pill. Seres’ $MCRB bac­te­ria pill is the pre­clin­i­cal SER-401. And the biotech land­ed a deal for MD An­der­son’s IP. The Park­er In­sti­tute will spon­sor a clin­i­cal tri­al to see if it works.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER